Core Viewpoint - Aomei Medical has successfully executed its share repurchase plan, exceeding the minimum funding requirement and demonstrating commitment to shareholder value [1][3]. Repurchase Plan Background - Aomei Medical's board approved a share repurchase plan on January 20, 2025, intending to use self-owned funds and special loan funds for stock repurchase, aimed at employee stock ownership plans [2]. - The repurchase price ceiling is set at 11.00 CNY per share, with a total funding range of no less than 50 million CNY and no more than 100 million CNY, to be completed within 12 months [2]. Repurchase Implementation Progress - As of October 31, 2025, Aomei Medical has repurchased 5.3062 million shares, representing 0.8379% of the total share capital, at an average price of 10.05 CNY per share, with a total expenditure of 50.6186 million CNY [3]. - The highest transaction price recorded was 10.05 CNY per share, and the lowest was 8.33 CNY per share, both below the set ceiling price [3]. Future Plans - Aomei Medical plans to continue its share repurchase according to market conditions within the remaining timeframe, adhering to relevant regulations and ensuring timely information disclosure [4].

Core Viewpoint - Aomei Medical (002950) announced a share buyback plan, indicating a strategic move to enhance shareholder value and confidence in the company's future performance [1] Summary by Categories Company Actions - As of October 31, 2025, Aomei Medical has repurchased a total of 5,306,200 shares through the Shenzhen Stock Exchange's centralized bidding system [1] - The repurchased shares represent 0.8379% of the company's current total share capital [1]

证券代码：002950 证券简称：奥美医疗 公告编号：2025-054 奥美医疗用品股份有限公司 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场情况 在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露义务。敬 请广大投资者关注后续公告，并注意投资风险。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购公司股份， 用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股（含），回购股份 的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），具体回购 资金总额以实际使用的资金总额为准。回购股份的实施期限为自公司董事会审议通过本次 回购方案之日起 12 个月内。具体内容详见公司分别于 2025 年 1 月 22 日、2025 ...

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Core Viewpoint - Aomei Medical (002950) reported a revenue of 2.597 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 5.98%, and a net profit attributable to shareholders of 349 million yuan, which is a year-on-year increase of 31.54% [1] Financial Performance - The company's revenue for the first three quarters reached 2.597 billion yuan, marking a 5.98% increase compared to the previous year [1] - The net profit attributable to shareholders was 349 million yuan, showing a significant year-on-year growth of 31.54% [1] Stock Market Reaction - On October 30, Aomei Medical's stock opened 5.78% higher at 10.61 yuan per share [1] - Following the opening, the stock price surged, reaching an increase of over 8% at one point during the trading session [1]

Core Insights - The company reported a total revenue of 2.597 billion yuan for Q3 2025, with a net profit attributable to shareholders of 349 million yuan [1] - Operating cash flow was recorded at 551 million yuan [1] - The company's latest debt-to-asset ratio stands at 29.98%, ranking 76th among disclosed peers, with an increase of 1.50 percentage points from the previous quarter [1] - The gross profit margin is 29.95%, ranking 91st among disclosed peers [1] - Return on equity (ROE) is reported at 9.35% [1] - The diluted earnings per share (EPS) is 0.55 yuan [1] - Total asset turnover is 0.50 times, while inventory turnover is 2.73 times [1] - The number of shareholders is 37,800, with the top ten shareholders holding 419 million shares, accounting for 66.22% of the total share capital [1] Shareholder Information - The top ten shareholders and their respective holdings are as follows: - 崔金海: 23.0% - 程宏: 15.1% - 万小香: 9.87% - 陈浩华: 9.69% - 香港中央结算有限公司: 2.83% - 崔星炜: 2.36% - 崔辉: 2.36% - 刘君平: 0.42% - 大家人寿保险股份有限公司-分红产品: 0.29% - 招商银行股份有限公司-永赢中证全指医疗器械交易型开放式指数证券投资基金: 0.25% [1]

Core Points - The board of directors and senior management of Aomei Medical guarantee the authenticity, accuracy, and completeness of the quarterly report, assuming legal responsibility for any misrepresentation or omissions [2][3][5] - The third-quarter financial report has not been audited [3][6] Financial Data Summary - The company does not require retrospective adjustments or restatements of previous accounting data [3] - There are no non-recurring profit and loss items applicable for the quarter [3] - The financial statements include a consolidated balance sheet, profit statement, and cash flow statement, all prepared as of September 30, 2025 [3][6] Shareholder Information - The report includes details on the total number of common shareholders and the top ten shareholders, with specific mention of shares held by executives under lock-up conditions [4][5] - There are no changes in the borrowing or returning of shares by the top ten shareholders due to transfer and financing activities [5] Other Important Matters - The company has not identified any other significant matters that require disclosure in this report [4]

Core Viewpoint - Aomei Medical (002950) reported a revenue of 2.597 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 5.98%, and a net profit attributable to shareholders of 349 million yuan, up 31.54% [1] Group 1: Financial Performance - In Q3 2025, the company achieved a revenue of 920 million yuan, with a year-on-year increase of 5.97%, and a net profit of 149 million yuan, reflecting a significant growth of 90.57% [1] - The company has maintained steady growth in performance while focusing on its core business and expanding into functional dressings, hospital infection prevention products, and hygiene care products [1] Group 2: Business Overview - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection prevention products, and home care products, being the only global enterprise with integrated, large-scale, and intelligent production in medical dressings and infection prevention products [1] - The company has been the leading exporter of medical dressings in China for 17 consecutive years since 2008, focusing on increasing its market share in overseas markets [2] Group 3: Product Development - The company is expanding its product line to include advanced dressing products, with a series of medical wound care products set to launch in 2024, including soft silicone foam dressings, hydrocolloid dressings, transparent dressings, and silicone gel scar patches [2] - Infection prevention products are designed for scenarios such as hospital infection control and surgical room management, with expectations for increased market penetration due to growing domestic emphasis on infection prevention [2] - Hygiene care products represent an extension of the company's medical device offerings into home care, although the brand presence in this category is still relatively small and in the early stages of development [2]

Core Insights - The company reported a third-quarter revenue of 920 million yuan, representing a year-on-year growth of 5.97% [1] - The net profit for the third quarter was 149 million yuan, showing a significant year-on-year increase of 90.57% [1] - For the first three quarters of 2025, the total revenue reached 2.597 billion yuan, with a year-on-year growth of 5.98% [1] - The net profit for the first three quarters was 349 million yuan, reflecting a year-on-year increase of 31.54% [1] - The basic earnings per share stood at 0.5519 yuan [1]

Revenue and Profit - Revenue for Q3 2025 reached ¥920,267,018.27, an increase of 5.97% year-over-year[5] - Net profit attributable to shareholders was ¥148,969,046.39, up 90.57% compared to the same period last year[5] - Basic earnings per share rose to ¥0.2352, reflecting a 90.60% increase year-over-year[5] - Total operating revenue for the current period reached ¥2,596,602,769, an increase of 5.95% compared to ¥2,450,075,783.88 in the previous period[17] - Net profit for the current period was ¥354,886,223.32, representing a 33.47% increase from ¥265,683,777.98 in the previous period[19] - Earnings per share (EPS) increased to ¥0.5519 from ¥0.4233, marking a growth of 30.38%[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,353,289,822.32, representing a growth of 5.82% from the previous year[5] - The company's total assets as of September 30, 2025, amount to ¥5,353,289,822.32, an increase from ¥5,058,919,305.88 at the beginning of the period[14] - Current assets total ¥2,196,817,121.60, up from ¥1,927,816,411.03 at the start of the period, indicating a growth of approximately 13.93%[13] - Total liabilities decreased slightly to ¥1,604,726,940.52 from ¥1,610,882,574.54, a reduction of 0.77%[15] - Long-term borrowings decreased significantly from ¥89,172,480.24 to ¥23,445,763.96, a decline of approximately 73.7%[14] Cash Flow - Cash flow from operating activities for the year-to-date was ¥551,316,700.13, an increase of 6.70%[5] - Cash flow from operating activities generated a net amount of ¥551,316,700.13, compared to ¥516,704,451.55 in the previous period, an increase of 6.67%[19] - The net cash flow from investment activities decreased by 116.36% to -¥209,626,167.84, primarily due to increased expenditures on idle fund management[10] - Cash flow from investment activities showed a net outflow of $209.63 million, compared to a net outflow of $96.89 million in the previous period, indicating a significant increase in investment expenditures[20] - Cash flow from financing activities resulted in a net outflow of $263.38 million, compared to a net outflow of $201.16 million in the previous period, highlighting increased financing costs[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,774, with no preferred shareholders having restored voting rights[11] - The top 10 shareholders hold a total of 23.02% of shares, with the largest shareholder, Cui Jinhai, owning 145,794,859 shares[11] - The top shareholder group includes Cui Jinhai, Wan Xiaoxiang, Cui Hui, and Cui Xingwei, who are identified as the company's controlling shareholders[11] - The company has a repurchase account holding 14,507,510 shares, which accounts for 2.29% of the total share capital[12] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥76,595,392.83, which is a 32.39% rise compared to the previous year[9] - Research and development expenses rose to ¥76,595,392.83, up from ¥57,853,716.21, indicating a significant investment in innovation[17] Future Outlook - The company anticipates continued growth in revenue and profit margins, driven by ongoing market expansion and new product development initiatives[5] Other Financial Metrics - Other comprehensive income after tax for the current period was ¥651,981.93, compared to a loss of ¥2,256,425.56 in the previous period, showing a positive turnaround[19] - The impact of exchange rate fluctuations on cash and cash equivalents was positive, contributing $4.29 million compared to a negative impact of $1.95 million in the previous period[20] - The company did not undergo an audit for the third quarter financial report, which may affect the reliability of the reported figures[21] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[22]